Q-omics provides the consensus-scored PDXP-DT profile across patient tissues and cancer cell-line models. PDXP-DT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDXP-DT is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, PDXP-DT RNA expression shows 15,447 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where PDXP-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDXP-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDXP-DT survival associations across molecular data types. PDXP-DT RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDXP-DT RNA expression–survival associations across cancer types. High PDXP-DT expression shows unfavorable associations in KIRC and THCA, but favorable associations in UCS, HNSC, BLCA and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDXP-DT RNA expression.
This table summarizes PDXP-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PDXP-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDXP-DT shows higher tumor expression in LUSC, LUAD, HNSC, KIRC, STAD and READ. The LUSC box plot shows higher PDXP-DT RNA expression in tumor versus normal tissue (log2 FC = +0.309, t-test p < 0.001).
This table shows molecular features associated with PDXP-DT in patient tissues and cancer cell lines. In patient samples, PDXP-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PDXP-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
